Toronto – November 25 th , 2019 (CNW) – Canada House Wellness Group Inc. (CSE: CHV) (“Canada House” or the “Company”), is pleased to announce its wholly owned subsidiary, Abba Medix Corp. (“Abba”), has entered into a two-year Medical Cannabis Supply Agreement (the “Supply Agreement”) with Franchise Cannabis Corp.’s (“Franchise”) wholly owned subsidiary, ACA Müller ADAG Pharma Vertriebs GmbH (“ACA Müller”), the first company in Germany licensed to distribute medical cannabis, for the sale and export of a minimum of 200 kg of pharmaceutical-grade EU-GMP cannabis flower into the European Union each year.

Under the Supply Agreement, Abba will acquire genetics from Europe’s first legal registered seed bank. Franchise’s collection of genetics consists of over 220 strains, bred by award winning and world-renowned breeder Charles Scott. Mr. Scott has won numerous globally recognized awards including an induction into the High Times Hall of Fame and 19 Cannabis Cups for THC strains such as Love Potion #1, Willie Nelson, and Pink Kush.

All products delivered under the Supply Agreement will be derived from plants grown in Abba’s cultivation facility using Franchise’s Genetics. At today’s exchange rates, the minimum quantity deliverable under the Supply Agreement equates to minimum approximate revenue of $1.2M CAD during each year of the Supply Agreement ($2.4M CAD over the two-year term). Subject to the existing right of first refusal under the supply agreement announced by Abba on October 31, 2019, Franchise will have the first right during the term to purchase all EU-GMP certified products shipped by Abba to the European Union at a set price.

ACA Müller and Abba will begin exports into Germany and other European Union countries upon Abba receiving EU-GMP certification by relevant authorities. Abba remains on track to obtain EUGMP Certification in mid-2020. “Based on multiple visits to Abba’s Pickering facility, we feel very confident with the prospect of Abba achieving EU-GMP status during 2020. With only 8 EU-GMP Certified facilities in the world this will be a huge accomplishment,” said Clifford Starke, Franchise Cannabis’s CEO. “We look forward to working with Chris and his team as long term partners for the production and distribution of EU-GMP medicinal cannabis.” “Establishing this relationship with the first licensed German distributor of medical cannabis is an exciting step for our business in diversifying our distribution into international markets,” said Chris Churchill-Smith, CEO of Canada House. “We have now signed high margin European supply agreements with cumulative minimum commitments representing approximately 20% of our nearterm annualized internal production, maximizing the profitability from Abba’s existing facility. Through this relationship, Abba will benefit from one of the most complete and sought-after genetics collections in the world. In addition, Abba’s Canadian medical cannabis patients will benefit from our ability to offer a wider variety of proven and established high THC medical cannabis strains grown in a craft setting.”

About Canada House Wellness Group Inc.

Canada House Wellness Group Inc. is the parent company of Abba Medix Corp., a Licensed Producer in Pickering, Ontario that produces high quality medical grade cannabis; Canada House Clinics Inc., with clinics across the country that work directly with primary care teams to provide specialized cannabinoid therapy services to patients suffering from simple and complex medical conditions; and Knalysis Technologies, a provider of fully customizable, cloud-based software that links physician, provider, and patient to data that supports treatment with medical cannabis.

Canada House Wellness Group’s goal is to become the leading cultivator of premium craft cannabis and provider of cannabinoid therapy, targeting the medical cannabis markets globally. Please visit

About Franchise Cannabis Corp.

Franchise Cannabis is a global, fully integrated medical cannabis company with a leading German distribution platform built upon the first license granted in March 2017. With two distribution facilities in Germany serving a vast pharmacy network, a licensed cultivator in Denmark currently producing high quality medical cannabis, and supply relationships with prestigious cannabis groups globally, Franchise is on the cutting edge of the European medical cannabis market. Franchise is the first legal registered seed bank in Europe and has one of the most complete and sought-after genetics collections in the world with over 220 strains, many of which have won Cannabis Cups and also has licensed CBD cultivation and extraction operations in Colombia and Uruguay. For more information, please visit:

For further information, please contact:

Liana Del Medico
Director of Communications & Investor Relations
Canada House Wellness Group Inc.

Franchise Cannabis Corp.

Cautionary Statement Regarding Forward-Looking Information. This press release contains forwardlooking statements, including statements that relate to, among other things, the Company’s clinic, production and technology businesses, its future plans, the Company’s markets, objectives, goals, strategies, intentions, beliefs, expectations and estimates, and can generally be identified by the use of words such as “may”, “will”, “could”, “should”, “would”, “likely”, “possible”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “plan”, “objective” and “continue” (or the negative thereof) and words and expressions of similar import. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making forwardlooking statements, and actual results may differ materially from those expressed or implied in such statements. Material assumptions used to develop forward-looking information in this news release include, among other things, the regulations related to cannabis use under the Access to Cannabis for Medical Purposes Regulations and the act respecting cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts, passed by the Canadian Federal government, making cannabis legal for recreational use by October 17, 2018; Company liquidity and capital resources, including the availability of additional capital resources to fund its activities; level of competition; the ability to adapt products and services to the changing market; the ability to attract and retain key executives; and the ability to execute strategic plans. Additional information about material factors that could cause actual results to differ materially from expectations and about material factors or assumptions applied in making forwardlooking statements may be found in the Company’s most recent annual and interim Management’s Discussion and Analysis under “Risk and Uncertainties” as well as in other public disclosure documents filed with Canadian securities regulatory authorities. The Company does not undertake any obligation to update publicly or to revise any of the forward-looking statements contained in this document, whether as a result of new information, future events or otherwise, except as required by law. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.